Retatrutide is a new pharmaceutical in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in research studies. By stimulating these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimately leads to significant slimming. While studies are still